Prevalence of avascular necrosis in idiopathic inflammatory myopathies: a single-centre experience.
AVN
avascular necrosis
myositis
osteonecrosis
Journal
Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501
Informations de publication
Date de publication:
02 03 2022
02 03 2022
Historique:
received:
02
03
2021
revised:
07
06
2021
pubmed:
28
6
2021
medline:
15
3
2022
entrez:
27
6
2021
Statut:
ppublish
Résumé
To assess the prevalence of avascular necrosis (AVN) in a large cohort of patients with idiopathic inflammatory myopathies (IIM) and define the major associated risk factors. We retrospectively reviewed the electronic medical records of all patients with a definitive diagnosis of IIM enrolled in our registry between 2003 and 2017, and followed until 2020. Pertinent demographic, clinical, serologic and imaging data were collected. A matched group of patients without AVN was then selected for comparison. A total of 1680 patients were diagnosed with IIM. Fifty-one patients developed AVN, with an overall prevalence of 3%. Musculoskeletal MRI was available for 1085 patients and AVN was present in 46 patients (43 lower extremities and 3 upper extremities MRI studies), with a relative prevalence of 4.2%. Most patients with AVN were Caucasian females (57%) with a mean (s.d.) age at diagnosis of 44.5 (12.4) years. Sixty-one percent had DM and 29% had PM. The median time from onset of IIM to diagnosis of AVN was 46 months. The hip joint was most commonly involved in 76% of cases, followed by the knee joint in 15% and shoulder joint in 9%. Some 81% of patients were asymptomatic. Established risk factors for AVN were not found to be associated with the development of AVN in IIM patients. Although mostly asymptomatic and incidental, the overall prevalence of AVN in IIM was 3% and the prevalence by MRI was 4.2%. None of the established risk factors was found to be associated with AVN development.
Identifiants
pubmed: 34175928
pii: 6310187
doi: 10.1093/rheumatology/keab493
pmc: PMC9123897
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
936-942Subventions
Organisme : NIAMS NIH HHS
ID : K08 AR077732
Pays : United States
Organisme : NIAMS NIH HHS
ID : K23 AR075898
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Neuromuscul Disord. 2013 Dec;23(12):1044-55
pubmed: 24268584
Lupus. 2014 Sep;23(10):1006-13
pubmed: 24786783
Radiographics. 2014 Jul-Aug;34(4):1003-28
pubmed: 25019438
Eur J Intern Med. 2016 Nov;35:e23-e24
pubmed: 27425656
Rheumatol Int. 2012 Jan;32(1):177-82
pubmed: 20711782
Autoimmun Rev. 2010 Sep;9(11):721-43
pubmed: 20621176
J Rheumatol. 2018 Jan;45(1):83-89
pubmed: 29142034
Neuromuscul Disord. 2004 May;14(5):337-45
pubmed: 15099594
J Clin Rheumatol. 2019 Jan;25(1):45-49
pubmed: 29794876
Ann Neurol. 1995 Nov;38(5):705-13
pubmed: 7486861
Gene. 2018 Sep 10;671:103-109
pubmed: 29859289
PLoS One. 2017 Jul 17;12(7):e0181069
pubmed: 28715432
Clin Orthop Relat Res. 2003 May;(410):213-24
pubmed: 12771833
Clin Rheumatol. 2017 Nov;36(11):2517-2524
pubmed: 28685377
World J Orthop. 2015 Sep 18;6(8):590-601
pubmed: 26396935
Arthritis Care Res. 1995 Sep;8(3):137-45
pubmed: 7654797
Lupus. 2017 Jun;26(7):715-722
pubmed: 27831540
Lupus. 2014;23(1):39-45
pubmed: 24335586
J Rheumatol. 1997 Apr;24(4):654-62
pubmed: 9101497
Ann Rheum Dis. 2001 Dec;60(12):1145-8
pubmed: 11709458
Semin Arthritis Rheum. 2002 Oct;32(2):94-124
pubmed: 12430099
Egypt J Immunol. 2010;17(1):29-40
pubmed: 22053607
N Engl J Med. 1975 Feb 13;292(7):344-7
pubmed: 1090839
J Am Acad Dermatol. 2002 Apr;46(4):626-36
pubmed: 11907524
J Clin Rheumatol. 2010 Aug;16(5):233-6
pubmed: 20577093
N Engl J Med. 1975 Feb 20;292(8):403-7
pubmed: 1089199
Radiology. 1986 Dec;161(3):739-42
pubmed: 3786725
Lupus. 2018 Jan;27(1):76-81
pubmed: 28530464